Significant protection from infection and AIDS progression after gastrointestinal and oral vaccinations, respectively, with a SIV DNA/rMVA vaccine

Nanotechnology for virus treatment

“…For instance, commercially manufactured 30–50 nm AgNPs were found to have affinity to gp120 on HIV-1 and thus blocked fusion in a dose-dependent manner by disrupting the gp120–CD4 interaction in a cell-based assay [ 202 ]. AgNPs have been combined with broadly neutralizing antibodies for HIV treatment [ 203 , 204 ]. Smaller 10 nm AgNPs were shown to effectively inhibit hemagglutination caused by H1N1 influenza A virus in vitro [ 205 ].…”